Humacyte Management
Management criteria checks 3/4
Humacyte's CEO is Laura Niklason, appointed in Jan 2004, has a tenure of 20.83 years. total yearly compensation is $2.63M, comprised of 23% salary and 77% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $1.09M. The average tenure of the management team and the board of directors is 3.3 years and 3.3 years respectively.
Key information
Laura Niklason
Chief executive officer
US$2.6m
Total compensation
| CEO salary percentage | 23.0% |
| CEO tenure | 20.8yrs |
| CEO ownership | 0.2% |
| Management average tenure | 3.3yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Humacyte: Navigating The FDA Uncertainty And ATEV's Potential
Sep 24Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Aug 16
Humacyte: Pioneering Vascular Solutions With High-Stakes Potential
Jul 17Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation
Jun 05Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High
May 14Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Feb 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$153m |
| Jun 30 2024 | n/a | n/a | -US$140m |
| Mar 31 2024 | n/a | n/a | -US$106m |
| Dec 31 2023 | US$3m | US$604k | -US$111m |
| Sep 30 2023 | n/a | n/a | -US$89m |
| Jun 30 2023 | n/a | n/a | -US$89m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$2m | US$500k | -US$12m |
| Sep 30 2022 | n/a | n/a | US$34m |
| Jun 30 2022 | n/a | n/a | US$28m |
| Mar 31 2022 | n/a | n/a | -US$26m |
| Dec 31 2021 | US$11m | US$500k | -US$26m |
| Sep 30 2021 | n/a | n/a | -US$85m |
| Jun 30 2021 | n/a | n/a | -US$71m |
| Mar 31 2021 | n/a | n/a | -US$69m |
| Dec 31 2020 | US$619k | US$75k | -US$67m |
Compensation vs Market: Laura's total compensation ($USD2.63M) is about average for companies of similar size in the US market ($USD2.18M).
Compensation vs Earnings: Laura's compensation has increased whilst the company is unprofitable.
CEO
Laura Niklason (61 yo)
20.8yrs
Tenure
US$2,625,702
Compensation
Dr. Laura E. Niklason, M.D., Ph D., serves as President and Chief Executive Officer at Humacyte, Inc. since November 2020. She founded Humacyte, Inc. in 2004 and served as its Chief Scientist from 2005 to...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 20.8yrs | US$2.63m | 0.19% $ 1.1m | |
| CFO, Chief Corporate Development Officer & Treasurer | 4yrs | US$1.35m | 0.018% $ 101.4k | |
| Chief Operating Officer | 5.5yrs | US$1.27m | no data | |
| Chief People Officer | no data | no data | no data | |
| Chief Commercial Officer | 3.3yrs | no data | no data | |
| Chief Medical Officer | 2.6yrs | US$1.53m | 0% $ 0 | |
| Chief Quality Officer | 2.3yrs | no data | no data | |
| Chief Regulatory Officer | 2.2yrs | no data | no data |
3.3yrs
Average Tenure
55yo
Average Age
Experienced Management: HUMA's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 20.8yrs | US$2.63m | 0.19% $ 1.1m | |
| Independent Director | 19.4yrs | US$76.76k | 0.050% $ 289.8k | |
| Director | 19.8yrs | US$71.76k | 0.40% $ 2.3m | |
| Independent Director | 3.3yrs | US$71.76k | 0% $ 0 | |
| Independent Director | no data | US$76.76k | 0% $ 0 | |
| Independent Chairman of the Board | 9.2yrs | US$96.76k | 0.032% $ 185.0k | |
| Independent Director | no data | US$79.26k | 0.0096% $ 55.5k | |
| Independent Director | 2.4yrs | US$71.76k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$71.76k | 0% $ 0 | |
| Independent Director | 2.2yrs | US$71.76k | 0% $ 0 | |
| Director | less than a year | no data | no data | |
| Director | less than a year | no data | no data |
3.3yrs
Average Tenure
64.5yo
Average Age
Experienced Board: HUMA's board of directors are considered experienced (3.3 years average tenure).